IP Library Granted Patent US 7,700,098
Granted Patent B2
US 7,700,098 · App. 11/342,020 · Granted Apr 20, 2010

Anti-interferon gamma antibodies and methods of use thereof

Assignee: Novimmune SA
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,098
App. No.
11/342,020
Filed
Jan 27, 2006
Granted
Apr 20, 2010
Kind
B2
Art Unit
1644
USPC
424/133.1
Abstract

The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hIFNγ), thereby modulating the interaction between IFNγ and its receptor, IFNγ-R, and/or modulating the biological activities of IFNγ. The invention also relates to the use of such anti-IFNγ antibodies in the prevention or treatment of immune-related disorders and in the amelioration of a symptom associated with an immune-related disorder.

Claims (16)

1. An isolated fully human monoclonal anti-IFNγ antibody or fragment thereof, wherein said antibody comprises:

(a) a V H CDR1 region consisting of the amino acid sequence SYAMS (SEQ ID NO:3);

(b) a V H CDR2 region consisting of the amino acid sequence AISGSGGSTYYADSVKG (SEQ ID NO:4),

(c) a V H CDR3 region consisting of the amino acid sequence DGSSGWYVPHWFDP (SEQ ID NO:5),

(d) a V L CDR1 region consisting of the amino acid sequence TRSSGSIASNYVQ (SEQ ID NO:8);

(e) a V L CDR2 region consisting of the amino acid sequence EDNQRPS (SEQ ID NO:9); and

(f) a V L CDR3 region consisting of the amino acid sequence QSYDGSNRWM (SEQ ID NO:10);

wherein said antibody or fragment thereof binds human IFNγ.

2. The antibody of claim 1 , wherein said antibody is an IgG isotype.

3. The antibody of claim 1 , wherein said antibody comprises the heavy chain variable amino acid sequence of SEQ ID NO: 2.

4. The antibody of claim 3 , wherein said antibody comprises the light chain variable amino acid sequence of SEQ ID NO: 7.

5. An isolated fully human monoclonal antibody, wherein said antibody comprises the heavy chain variable amino acid sequence of SEQ ID NO: 2, wherein said antibody binds human IFNγ.

6. The antibody of claim 5 , wherein said antibody further comprises the light chain variable amino acid of SEQ ID NO: 7, wherein said antibody binds human IFNγ.

7. The antibody of claim 5 , wherein said antibody is an IgG isotype.

8. A pharmaceutical composition comprising an antibody of claim 1 and a carrier.

9. A pharmaceutical composition comprising an antibody of claim 5 and a carrier.

Assignments (3)
MERGER Recorded Feb 28, 2020
From: EMACO SA
To: SWEDISH ORPHAN BIOVITRUM AG
Reel/Frame 052049/0890 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2019
From: NOVIMMUNE SA
To: EMACO SA
Reel/Frame 049722/0868 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2006
From: FERLIN, WALTER; FISCHER, NICOLAS; ELSON, GREG; LEGER, OLIVIER
To: NOVIMMUNE S.A.
Reel/Frame 018138/0852 →
Continuity (2)
Provisional Application 6064821900 · Jan 27, 2005
Related Publication 20060263363A1 · Nov 23, 2006